ESLA · Estrella Immunopharma, Inc.
$0.72
-0.02 (-3.12%)
At close · Aug 7
Going-concern doubt
— flagged May 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, management has determined that there is a substantial doubt about its ability to continue as a going concern.”View the 10-Q filed May 18, 2026
Market Cap
$31.09M
Shares
43.03M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$13.06M
-78.7%
FY2025
Diluted EPS
-$0.35
-29.6%
FY2025
Operating Cash Flow
-$1.79M
+88.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| $10.24M | $10.25M | $4.11M | — | — | |
| $3.01M | $2.81M | $3.2M | — | — | |
| $13.25M | $13.06M | $7.31M | — | — | |
| -$13.25M | -$13.06M | -$7.31M | -$1.57M | -$249.15K | |
| — | — | — | $654.07K | $1428 | |
| — | — | — | $654.07K | — | |
| -$13.25M | -$13.06M | -$7.31M | -$915.46K | -$247.72K | |
| — | $838 | $1625 | $80.65K | $0 | |
| -$13.25M | -$13.06M | -$7.31M | -$996.1K | -$247.72K | |
| USD/shares | — | -$0.35 | -$0.27 | — | — |
| USD/shares | — | -$0.35 | -$0.27 | — | — |
| shares | — | 36.82M | 27.1M | — | 1.18M |
| shares | — | 36.82M | 27.1M | — | 1.18M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 3.39×
EV/EBIT
—
P/E (TTM)
—
Peer median 0.70×
Peer medians compare against the 256 similar-size Biotechnology companies (of 521 listed).